Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

Title

2025 Biotech Layoff Surge:
10x Genomics Cuts 8%, NGM Bio Sheds 75% Amid Industry-Wide Reductions

10x Genomics has reduced its global workforce by 8% as part of wider biotech industry layoffs in 20251 5.
NGM Bio implemented a drastic reduction, shedding 75% of its staff, and is halting further investment in preclinical research, including almost all research positions2 5.
The biopharma industry saw at least 63 layoff rounds in Q1 2025, including eight company closures, according to the Fierce Biotech Layoff Tracker3 5.
Biopharma layoffs rose by 3% in 2024 compared to 2023, indicating ongoing sector instability.
The average percentage workforce reduction among companies reporting figures in early 2025 was 43%3.
Cell and gene therapy biotechs accounted for nearly a third of the documented layoffs in Q1 2025, reflecting particular stress in this subsector3 5.
1,965 jobs were lost from 20 companies that disclosed specific numbers in Q1 2025, while many others only shared percentage reductions or did not report numbers3.
Other notable layoffs in 2025 include reductions at NIH (including the National Cancer Institute), Biomea, Unity, Mammoth, and Ono Pharma5.
The sector’s deep uncertainty is being driven by factors including market shifts, geopolitical changes, and companies refocusing pipelines, especially away from preclinical or early-stage research2 3 5.